Generic Tabrecta Availability
Last updated on May 7, 2025.
Tabrecta is a brand name of capmatinib, approved by the FDA in the following formulation(s):
TABRECTA (capmatinib hydrochloride - tablet;oral)
-
Manufacturer: NOVARTIS PHARM
Approval date: May 6, 2020
Strength(s): EQ 150MG BASE [RLD], EQ 200MG BASE [RLD]
Is there a generic version of Tabrecta available?
No. There is currently no therapeutically equivalent version of Tabrecta available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tabrecta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Tablet formulation of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
Patent 10,596,178
Issued: March 24, 2020
Inventor(s): Goncalves Elisabete & Tauchmann Christin & Yen Shau-Fong & Vippagunta Sudha & Zong Zhixin
Assignee(s): Novartis AGThe present invention is related to tablets comprising of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,-2-b][1,2,4]triazin-2-yl]benzamide, processes for the production thereof, and uses in the treatment of certain cancers.
Patent expiration dates:
- July 22, 2035✓
- July 22, 2035
-
Imidazotriazines and imidazopyrimidines as kinase inhibitors
Patent 12,084,449
Issued: September 10, 2024
Inventor(s): Zhuo; Jincong et al.
Assignee(s): INCYTE HOLDINGS CORPORATION (Wilmington, DE); INCYTE CORPORATION (Wilmington, DE)The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
Patent expiration dates:
- November 19, 2027✓
- November 19, 2027
-
Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
Patent 12,208,101
Issued: January 28, 2025
Inventor(s): Goncalves; Elisabete et al.
Assignee(s): NOVARTIS AG (Basel, CH)The present invention is related to tablets comprising of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, processes for the production thereof, and uses in the treatment of certain cancers.
Patent expiration dates:
- July 22, 2035✓
- July 22, 2035
-
Imidazotriazines and imidazopyrimidines as kinase inhibitors
Patent 7,767,675
Issued: August 3, 2010
Inventor(s): Zhuo; Jincong et al.
Assignee(s): Incyte Corporation (Wilmington, DE)The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
Patent expiration dates:
- November 19, 2032✓✓
- November 19, 2032
-
Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
Patent 8,420,645
Issued: April 16, 2013
Inventor(s): Weng Lingkai & Qiao Lei & Zhou Jiacheng & Liu Pingli & Pan Yongchun
Assignee(s): Incyte CorporationThe present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.
Patent expiration dates:
- June 5, 2031✓✓
- June 5, 2031
-
Imidazotriazines and imidazopyrimidines as kinase inhibitors
Patent 8,461,330
Issued: June 11, 2013
Inventor(s): Zhuo Jincong & Xu Meizhong & He Chunhong & Zhang Colin & Qian Ding-Quan & Burns David M. & Li Yun-Long & Metcalf Brian & Yao Wenqing
Assignee(s): Incyte CorporationThe present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
Patent expiration dates:
- November 19, 2027✓✓
- November 19, 2027
-
Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
Patent 8,901,123
Issued: December 2, 2014
Inventor(s): Weng Lingkai & Qiao Lei & Zhou Jiacheng & Liu Pingli & Pan Yongchun
Assignee(s): Incyte CorporationThe present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.
Patent expiration dates:
- May 20, 2029✓
- May 20, 2029
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- May 6, 2025 - NEW CHEMICAL ENTITY
- May 6, 2027 - INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE A MUTATION THAT LEADS TO MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING AS DETECTED BY AN FDA-APPROVED TEST
More about Tabrecta (capmatinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
